HSD17B13 and metabolic dysfunction-associated steatotic liver disease: Our RNAi therapeutic approach, to suppress Hsd17b13 levels in adult mice with existing HFD‐induced liver steatosis to decrease hepatic triglyceride storage is a translational approach to investigate the role of Hsd17b13 in MASLD.